Zobrazeno 1 - 10
of 44
pro vyhledávání: '"C. Kaltenecker"'
Autor:
Johannes J. Kovarik, Anna K. Kämpf, Fabian Gasser, Anna N. Herdina, Monika Breuer, Christopher C. Kaltenecker, Markus Wahrmann, Susanne Haindl, Florian Mayer, Ludwig Traby, Veronique Touzeau-Roemer, Katharina Grabmeier-Pfistershammer, Manuel Kussmann, Oliver Robak, Harald Willschke, Care Ay, Marcus D. Säemann, Klaus G. Schmetterer, Robert Strassl
Publikováno v:
Frontiers in Cellular and Infection Microbiology, Vol 11 (2021)
This study aimed to determine the specific cytokine profile in peripheral blood during the early onset of COVID-19 infection. This was a cross-sectional exploratory, single center study. A total of 55 plasma samples were studied. Serum samples of adu
Externí odkaz:
https://doaj.org/article/4bf28112b3c14942b95ed99c9282e9a8
Autor:
Marlies Antlanger, Oliver Domenig, Christopher C. Kaltenecker, Johannes J. Kovarik, Vincent Rathkolb, Martin M. Müller, Elisabeth Schwaiger, Manfred Hecking, Marko Poglitsch, Marcus D. Säemann, Chantal Kopecky
Publikováno v:
Diabetes, Obesity and Metabolism. 24:816-826
Sodium glucose co-transporter-2 inhibitors (SGLT-2i) improve cardiorenal outcomes in patients with chronic kidney disease (CKD), with and without type 2 diabetes. The molecular mechanisms underlying these pleiotropic effects remain unclear, yet it is
Autor:
Johannes M Werzowa, Marcus D Säemann, Alexander Mohl, Michael Bergmann, Christopher C Kaltenecker, Wolfgang Brozek, Andreas Thomas, Michael Haidinger, Marlies Antlanger, Johannes J Kovarik, Chantal Kopecky, Peter X K Song, Klemens Budde, Julio Pascual, Manfred Hecking
Publikováno v:
PLoS ONE, Vol 13, Iss 3, p e0193569 (2018)
Treating hyperglycemia in previously non-diabetic individuals with exogenous insulin immediately after kidney transplantation reduced the odds of developing Posttransplantation Diabetes Mellitus (PTDM) in our previous proof-of-concept clinical trial.
Externí odkaz:
https://doaj.org/article/f8a8ec4955924ee88d958c986166e090
Autor:
null Marlies Antlanger, null Oliver Domenig, null Christopher C Kaltenecker, null Johannes J Kovarik, null Vincent Rathkolb, null Martin M Müller, null Elisabeth Schwaiger, null Manfred Hecking, null Marko Poglitsch, null Marcus D Säemann, null Chantal Kopecky
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::45a2851c593424f1b42535f473fae92b
https://doi.org/10.1111/dom.14639/v2/response1
https://doi.org/10.1111/dom.14639/v2/response1
Autor:
Johannes J. Kovarik, Christopher C. Kaltenecker, Oliver Domenig, Chantal Kopecky, Marcus D. Säemann, Marko Poglitsch, Marlies Antlanger
Publikováno v:
Diabetes Therapy
Background Renin–angiotensin–aldosterone system (RAAS) blockade with angiotensin-converting enzyme inhibitors (ACEi) or angiotensin receptor blockers (ARB) is the cornerstone of antihypertensive treatment in patients with chronic kidney disease (
Autor:
Johannes J. Kovarik, Yuliya Lytvyn, David Z.I. Cherney, Marko Poglitsch, Bruce A. Perkins, Kerry-Anne Rye, Marlies Antlanger, Christopher C. Kaltenecker, Chantal Kopecky, Oliver Domenig, Marcus D. Säemann
Publikováno v:
Diabetologia. 62:1090-1093
Autor:
Roland Hellinger, Masudur Rahman, Georg A. Böhmig, Marcus D. Säemann, Nadja Grobe, Johannes J. Kovarik, Chantal Kopecky, Farsad Eskandary, Johannes Stegbauer, Christopher C. Kaltenecker, Gabriela A. Berlakovich, Christian W. Gruber, Harun Fajkovic, Marko Poglitsch, Renate Kain, Oliver Domenig, Marlies Antlanger
Publikováno v:
Circ Res
Rationale: Kidney homeostasis is critically determined by the coordinated activity of the renin-angiotensin system (RAS), including the balanced synthesis of its main effector peptides Ang (angiotensin) II and Ang (1–7). The condition of enzymatic
Autor:
Markus Wahrmann, Nicolas Kozakowski, Farsad Eskandary, Georg A. Böhmig, Gregor Bond, Philip F. Halloran, Jeff Reeve, Heinz Regele, Luis G. Hidalgo, Helmuth Haslacher, Lukas Baumann, Ammon Handisurya, Martin Posch, Anton Staudenherz, Christopher C. Kaltenecker, Marie-Bernadette Aretin, Rainer Oberbauer
Publikováno v:
Journal of the American Society of Nephrology. 29:591-605
Late antibody-mediated rejection (ABMR) is a leading cause of kidney allograft failure. Uncontrolled studies have suggested efficacy of the proteasome inhibitor bortezomib, but no systematic trial has been undertaken to support its use in ABMR. In th
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Autor:
Sebastian Bernhofer, Johannes J. Kovarik, Oliver Domenig, Christopher C. Kaltenecker, Marcus D. Säemann, Chantal Kopecky, Marko Poglitsch, Marlies Antlanger
Publikováno v:
Annals of Medicine. 49:525-533
Direct renin inhibition (DRI) is clinically inferior to other blockers of the renin-angiotensin system (RAS). Thus far, the underlying molecular causes of this finding remain unknown.Twenty four patients with non-diabetic chronic kidney disease (CKD)